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Abstract
Toxic Epidermal Necrolysis and Steven-Johnson syndrome are entities on a spectrum of cutaneous
reactions that usually occur as an idiosyncratic reaction to certain drugs. The distinction between
TEN and SJS is based on the percentage of skin involved with SJS being less than 10% and TEN being
more than 30%. They exhibit severe skin blistering and sloughing with mucosal involvement and can
be fatal in many cases. Discontinuation of the offending agent is mandatory together with reduction
of skin manipulation and avoiding infection. Plasmapharesis, intravenous immunoglobulins and
immunosuppressants have been used with conflicting results. In this manuscript we are describing
a 22 year old female patient from Egypt who presented with severe skin sloughing with mucosal
involvement following carbamazepine therapy. The incriminated drug was discontinued and urgent
life saving therapy in the form of broad spectrum antibiotic, immunosuppression with
cyclophosphamide, Intensive Care Unit admission and nursing care was started followed by
dramatic response. The clinical presentation, pathogenesis and modalities of treatment will be
described in details.
Introduction
TEN and SJS are severe, acute and rare mucocutaneous dis-
eases that are usually elicited by drugs. Many different
groups of drugs can cause TEN, including anticonvulsants,
nonsteroidal anti-inflammatory drugs, allopurinol and
antibiotics. TEN is characterized by extensive blistering,
full-thickness necrosis, and destruction of the epidermis.
TEN and SJS are the same disease spectrum that can
present with differences in severity and area of involve-
ment. SJS is less extensive and affects less than 10% of the
body surface area while TEN involves more than 30%
BSA. The mortality rate of SJS is up to 5%, while the mor-
tality among patients with TEN may exceed 30%. TEN
patients should be treated in a burn center or intensive
care unit. No optimal treatment for SJS and TEN has been
developed. But recently, IVIG has been suggested for
patients with TEN. This case report aims to sensitize read-
ers to the possibility of the occurrence of this rare compli-
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cation following carbamazepine therapy and the
successful use of cyclophosphamide to dramatically cure
the condition.
Case presentation
A 22-year-old Caucasian female with a BMI of 35 kg/m2
from Egypt, with no past medical history of clinical signif-
icance presented to the outpatient clinic one month after
a normal delivery with severe headache and blurring of
vision. Fundus examination showed evidence of bilateral
papilledema, brain CT scan was normal and the patient
was diagnosed with benign intracranial hypertension. She
underwent therapeutic CSF aspiration and was main-
tained on carbamazepine and acetazolamide to decrease
intracranial pressure.
After 5 days of carbamazepine therapy the patient started
to complain of generalized skin eruptions in the form of
irregularly shaped macules distributed on the face, trunk,
upper and lower limbs as illustrated in figure 1. This was
followed by grayish discoloration and mottling of the skin
and mucous membranes. Mucosal involvement was
noticed in the form of conjunctival injection and oral
lesions.
The patient was admitted to the Intensive Care Unit with
high fever, extensive skin sloughing, clinical evidence of
dehydration and severe pain mandating continuous mor-
phine infusion. Skin lesions showed a positive Nikolsky
sign and ophthalmological examination revealed bilateral
conjunctivitis. Initial workup revealed clinical and labora-
tory evidence of sepsis in the form of hypotension, leuko-
cytosis, elevated Erythrocyte sedimentation rate,
metabolic acidosis, high serum lactate level and otherwise
normal biochemical profile. Skin lesions were pathogno-
monic of Toxic Epidermal Necrolysis (TEN) with more
than 30% skin involvement. Detailed history taking
revealed the recent introduction of carbamazepine ther-
apy for treatment of pseudotumour cerebri. Drug induced
TEN was suspected and carbamazepine was withdrawn.
The patient was managed with Lactated ringer solution
together with the use of sterile skin dressings to reduce
pain and risk of infection. The patient was started on
immunosuppressant therapy in the form of cyclophos-
phamide. Blood and skin cultures were positive for pseu-
domonas and patient was started on imipinem/cilastatin.
Dramatic improvement in the patient condition was
noticed after one week of cyclophosphamide therapy with
complete resolution of the skin lesions, mucosal involve-
ment and pain as shown in figure 2. Metabolic acidosis,
leukocytosis and fever resolved together with the normal-
ization of serum lactate level. Ophthalmological follow
Toxic epidermal necrolysis with Generalized sloughing of the  epidermis involving more than 30% of the body surface area Figure 1
Toxic epidermal necrolysis with generalized slough-
ing of the epidermis involving more than 30% of the 
body surface area.
Demonstrating complete resolution of the skin lesions fol- lowing cyclophosphamide therapy Figure 2
Demonstrating complete resolution of the skin 
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up revealed resolution of the conjunctivitis with no evi-
dence of scarring.
Discussion
Alan Lyell described TEN in 1956, describing the condi-
tion as "an eruption resembling scalding of the skin [1].
TEN is characterized by epidermal loss suggestive of severe
scalding. In that same year, Lang and Walker also
observed a patient with TEN [2], which was originally
described by Debre et al in 1939 [3].
TEN is a rare disease. The incidence in adults is estimated
to be between 0.4 and 1.2 cases per 1 million people per
year [4-9]. Carbamazepine caused SJS/TEN in a frequency
of 14 per 100000 users [10]. Death often occurs early in
the course of the disease with sepsis being the most fre-
quent cause. Pseudomonas aeruginosa and  Staphylococcus
aureus are the predominant organisms involved. The mor-
tality rate of SJS is up to 5%, while the mortality among
patients with TEN may exceed 30%. Mortality is increased
significantly in patients who are at the extremes of age and
in relation to the percentage of denuded skin [8,11].
The actual pathophysiologic mechanism of TEN remains
uncertain; however, it seems apparent that an exposure to
certain drugs plays a significant role in triggering the dis-
ease process. These drugs include anticonvulsants, such as
phenobarbital, phenytoin, valproic acid; antibiotics such
as sulfonamides, aminopenicillins, quinolones, and
cephalosporins; anti-inflammatory drugs; acetami-
nophen; allopurinol; and corticosteroids [12], The rela-
tively new antiepileptic drug; lamotrigine has also been
described as a triggering factor. The incidence of cross
reactivity among the aromatic anticonvulsants: car-
bamazepine, phenytoin, phenobarbital, which share an
arene oxide intermediary, is greater than 75% [13].
Carbamazepine is being increasingly prescribed for vari-
ous indications specially pain control and this may be a
reason for the increased incidence of SJS/TEN due to car-
bamazepine. This case report describes the occurrence of
TEN after carbamazepine therapy used to treat a patient
with psudotumour cerebri. In 2004, a genetic marker, the
human leukocyte antigen HLA-B 1502, was reported to be
strongly associated with carbamazepine-induced SJS or
TEN in Han Chinese [14].
TEN is believed to be an immune-related cytotoxic reac-
tion aimed at destroying keratinocytes that express drug
related antigens. It mimics a hypersensitivity reaction,
with its characteristic delayed reaction to an initial expo-
sure and an increasingly rapid reaction with repeated
exposure. Explanations for the generalized nature of TEN
include the belief that tumor necrosis factor-α (TNF-α)
which is derived from macrophages and keratinocytes is
over expressed in the epidermis and play an important
role in epidermal destruction directly through apoptosis,
indirectly through stimulating cytotoxic T lymphocytes, or
both.
Treatment of TEN focuses on early withdrawal of the caus-
ative agent and referral of the patient to a burn center for
critical care and appropriate wound management. Local
care of the denuded skin areas is of utmost importance to
avoid infection. Bacterial cultures should be withdrawn
and antibiotics started with the first sign of infection to
prevent septicemia
Ophthalmological follow-up is recommended to prevent
conjunctival scarring. Systemic therapy for TEN remains
controversial with no standard guidelines available. The
use of systemic corticosteroids is very controversial and a
consensus has not been reached so far; plasmapharesis,
immunoglobulins and immunosuppressant drugs have
been tried with non-conclusive results [15-17]. In our
patient the early use of cyclophosphamide resulted in dra-
matic improvement of skin sloughing and mucosal dam-
age.
Conclusion
TEN is a rare but serious disorder that most commonly
occurs secondary to specific drug exposure. TEN is a gen-
eralized disease that involves skin and mucous mem-
branes of a large body surface area. Skin infection and
sepsis are the most common complications and care must
be given for prevention and early treatment of sepsis.
Many treatment modalities have been used including
plasmapharesis, immunoglobulins and immunosuppres-
sants but with conflicting results. In our patient the early
use of cyclophosphamide resulted in a rapid dramatic
improvement of the skin lesions together with the resolu-
tion of the signs of sepsis. This case report aims to sensi-
tize readers to the possibility of the occurrence of this rare
complication following carbamazepine therapy. Ade-
quate awareness about the culprit drugs in this life threat-
ening complication will help physicians in preventing
them by judicious use of these drugs.
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